Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Janux Therapeutics Initiates Phase 1b Expansion Studies In Ongoing ENGAGER-PSMA-01 Trial

Author: Benzinga Newsdesk | May 05, 2025 08:37am
  • Phase 1b expansion study initiated in taxane-naïve mCRPC patients
  • Updated data from Phase 1a dose escalation support initiation of Phase 1b dose expansion
  • Updates on JANX007 and JANX008 expected in the second half of 2025
  • Janux to host R&D Day in mid-2025 highlighting preclinical pipeline progression to the clinic

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the initiation of Phase 1b expansion studies in the ongoing ENGAGER-PSMA-01 trial.

Posted In: JANX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist